CN115698071A - 抗-cd6抗体组合物以及用于治疗和降低包括covid-19在内的冠状病毒的不利效应的方法 - Google Patents

抗-cd6抗体组合物以及用于治疗和降低包括covid-19在内的冠状病毒的不利效应的方法 Download PDF

Info

Publication number
CN115698071A
CN115698071A CN202180039042.4A CN202180039042A CN115698071A CN 115698071 A CN115698071 A CN 115698071A CN 202180039042 A CN202180039042 A CN 202180039042A CN 115698071 A CN115698071 A CN 115698071A
Authority
CN
China
Prior art keywords
antibody
seq
ser
covid
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180039042.4A
Other languages
English (en)
Chinese (zh)
Inventor
P·纳伊尔
J·E·M·卡西米洛
K·马祖母达尔肖
U·布甘尼
S·N·埃塞里
M·S·罗摩克里希南
T·克罗姆贝特拉莫斯
K·莱昂蒙松
M·拉莫斯苏扎特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Immunologia Molecular
Biocon Ltd
Original Assignee
Centro de Immunologia Molecular
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU2020000027A external-priority patent/CU20200027A7/es
Application filed by Centro de Immunologia Molecular, Biocon Ltd filed Critical Centro de Immunologia Molecular
Publication of CN115698071A publication Critical patent/CN115698071A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180039042.4A 2020-04-04 2021-04-03 抗-cd6抗体组合物以及用于治疗和降低包括covid-19在内的冠状病毒的不利效应的方法 Pending CN115698071A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202041014994 2020-04-04
IN202041014994 2020-04-04
CU2020000027A CU20200027A7 (es) 2020-04-17 2020-04-17 Uso de anticuerpos monoclonales anti-cd6 no depletantes en el tratamiento de la tormenta de citocinas
CUCU-2020-0027 2020-04-17
PCT/IB2021/052793 WO2021199006A1 (en) 2020-04-04 2021-04-03 Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Publications (1)

Publication Number Publication Date
CN115698071A true CN115698071A (zh) 2023-02-03

Family

ID=77928142

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180039042.4A Pending CN115698071A (zh) 2020-04-04 2021-04-03 抗-cd6抗体组合物以及用于治疗和降低包括covid-19在内的冠状病毒的不利效应的方法

Country Status (15)

Country Link
US (1) US20230151107A1 (https=)
EP (1) EP4126961A4 (https=)
JP (1) JP2023526890A (https=)
KR (1) KR20220165267A (https=)
CN (1) CN115698071A (https=)
AU (1) AU2021247258A1 (https=)
BR (1) BR112022018936A2 (https=)
CA (1) CA3174566A1 (https=)
CL (1) CL2022002684A1 (https=)
CO (1) CO2022014199A2 (https=)
IL (1) IL296487A (https=)
MX (1) MX2022012229A (https=)
TW (1) TW202200202A (https=)
WO (1) WO2021199006A1 (https=)
ZA (1) ZA202210032B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
JP7065085B2 (ja) * 2016-10-18 2022-05-11 バイオコン・リミテッド Ｃｄ６のリン酸化を低減させるためのイトリズマブの使用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1175957A (zh) * 1995-11-17 1998-03-11 分子免疫中心 抗cd6的单克隆抗体和它们的用途
WO2009113083A1 (en) * 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
CN102292107A (zh) * 2008-11-25 2011-12-21 奥尔德生物制药公司 增加白蛋白和/或减少crp的il-6拮抗剂
CN109311992A (zh) * 2016-06-15 2019-02-05 克利夫兰临床基金会 用于治疗t细胞介导疾病的新型抗cd6抗体
WO2019169015A1 (en) * 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021130195A1 (en) * 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Method of treating virus infection using a tlr7 agonist

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1175957A (zh) * 1995-11-17 1998-03-11 分子免疫中心 抗cd6的单克隆抗体和它们的用途
WO2009113083A1 (en) * 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
CN101970493A (zh) * 2008-03-14 2011-02-09 百康有限公司 单克隆抗体及其方法
CN102292107A (zh) * 2008-11-25 2011-12-21 奥尔德生物制药公司 增加白蛋白和/或减少crp的il-6拮抗剂
CN109311992A (zh) * 2016-06-15 2019-02-05 克利夫兰临床基金会 用于治疗t细胞介导疾病的新型抗cd6抗体
WO2019169015A1 (en) * 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PUJA MEHTA: "COVID-19: consider cytokine storm syndromes and immunosuppression", LANCET, 28 March 2020 (2020-03-28), pages 1033 - 1034 *
SHUBHAM ATAL: "Approval of Itolizumab for COVID‑19: A Premature Decision or Need of The Hour", BIODRUGS, 13 October 2020 (2020-10-13), pages 705 - 711 *
张竞文: "新型冠状病毒引起的细胞因子风暴及其药物治疗", 中国药学杂志, vol. 55, no. 5, 25 February 2020 (2020-02-25), pages 333 - 336 *

Also Published As

Publication number Publication date
EP4126961A4 (en) 2024-07-17
TW202200202A (zh) 2022-01-01
KR20220165267A (ko) 2022-12-14
MX2022012229A (es) 2022-10-27
CL2022002684A1 (es) 2023-03-24
US20230151107A1 (en) 2023-05-18
WO2021199006A1 (en) 2021-10-07
EP4126961A1 (en) 2023-02-08
ZA202210032B (en) 2024-09-25
AU2021247258A1 (en) 2022-11-10
JP2023526890A (ja) 2023-06-26
BR112022018936A2 (pt) 2022-12-06
IL296487A (en) 2022-11-01
CA3174566A1 (en) 2021-10-07
CO2022014199A2 (es) 2022-11-08

Similar Documents

Publication Publication Date Title
CN115698071A (zh) 抗-cd6抗体组合物以及用于治疗和降低包括covid-19在内的冠状病毒的不利效应的方法
US11364227B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
CA3174634A1 (en) Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
RU2828013C1 (ru) Композиции антител к cd6 и способы лечения и снижения негативных последствий коронавируса, включая covid-19
CN108778333A (zh) 严重社区获得性肺炎的治疗
HK40078901A (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
US20220025019A1 (en) Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
EP4137144A2 (en) Peptide for the treatment of cytokine storm syndrome
JP2023541921A (ja) Ｃｏｖｉｄ－１９肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験（ｅｍｐａｃｔａ）の結果
JP2023518812A (ja) Ｃｏｖｉｄ１９肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ
RU2834279C1 (ru) Пептид для лечения синдрома цитокинового шторма
RU2837859C1 (ru) Лечение коронавирусной инфекции
EP4153310B1 (en) Bbeta-15-42 for the treatment of viral endothelitis
US12115150B2 (en) Biomarkers of coronavirus pneumonia
Elmenshawy et al. Different Therapeutic Modalities for management of COVID-19
Krishnaswami et al. 16 Therapeutics for
JP2023518815A (ja) Ｉｌ６アンタゴニストによるｃｏｖｉｄ－１９肺炎を含む肺炎の治療方法
JP2023156545A (ja) コロナウイルスによる感染症治療用の医薬組成物
JP2023156533A (ja) コロナウイルスによる感染症治療用の医薬組成物
Sokołowska et al. Monoconal antibodies to treat COVID-19 and complications from SARS-CoV-2 infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078901

Country of ref document: HK